BHCM
NERV icon

Brevan Howard Capital Management’s Minerva Neurosciences NERV Stock Holding History

Brevan Howard Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,629
Closed -$172K – 2417
2026
Q1 		$172K Buy
+28,629
New +$164K ﹤0.01% 1933

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brevan Howard Capital Management's NERV Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Minerva Neurosciences (NERV) in Q2 2026, closing a stake of 28,629 shares — an estimated $172K sold.

Brevan Howard Capital Management first reported a position in NERV in Q1 2026 and held it in 1 quarter. The position peaked at $172K in Q1 2026. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Minerva Neurosciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 28,629 Minerva Neurosciences shares in Q2 2026, an estimated $172K.
  • Brevan Howard Capital Management first reported a position in Minerva Neurosciences in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Minerva Neurosciences position peaked at $172K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.